Huadong Medicine Receives NMPA Approval for HDM2012 Clinical Trials in Advanced Solid Tumors
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
Company
Optoseeker Biotech and BioMap Collaborate to Accelerate Antibody Therapeutics Development
Optoseeker Biotech, a leader in advanced life science instrumentation, and BioMap, a pioneer in life...
Wondfo Biotech’s MSI Detection Kit Granted NMPA Marketing Clearance
Guangzhou-based Wondfo Biotech (SHE: 300482) announced that the National Medical Products Administration (NMPA) has granted...
Zhongke Yian Receives NMPA Approval for Innovative Sirolimus-Eluting Coronary Stent
ZhongKe Yian Medical Technology (Beijing) Co., Ltd. has secured approval from China’s National Medical Products...
NMPA Approves World’s First Plant-Based Human Albumin for Liver Cirrhosis Treatment
China’s National Medical Products Administration (NMPA) has approved the world’s first plant-based human albumin, a...
KANTE Biotech’s Yilijia Wins NMPA Category III License for Pancreatic Cancer Early Detection
KANTE (Shenzhen) Biotechnology Co., Ltd (“Kante-bio”) announced that it has received a Category III medical...
WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings
WuXi Biologics (HKG: 2269) announced on July 21, 2025, that five of its manufacturing facilities...
Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment
Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike...
Novo Nordisk’s Ozempic Approved for Kidney Protection in China, Pioneering Glycemic and Renal Control
The National Medical Products Administration has granted approval to Novo Nordisk’s (NYSE: NVO) once-weekly semaglutide...
Shanghai Wankexin Biotech to Acquire Stake in Chengdu Kanghua Biological for RMB 1.851 Billion
Shanghai Wankexin Biotechnology Partnership Enterprise (Limited Partnership) (“Wankexin Biotech”), a subsidiary of the Shanghai Biomedicine...
Bayer and JD Health Collaborate on Dulcolax-Lactulose to Expand China’s Digestive-Health Market
Bayer (ETR: BAYN) and JD Health (HKG: 6618) have launched Dulcolax-branded lactulose in a pioneering...
Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension
US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500...
VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies
VivaVision Biotech recently announced the successful closing of its D2+ funding round, raising 140 million...
Youcare Pharma Subsidiary Gains NMPA Clearance for Phase I Study of siRNA Hypertension Drug YKYY029
China-based Youcare Pharma (SHA: 688658) announced that its subsidiary Youcare InnoTech and partner Hangzhou Tianlong...
GSK’s Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma
UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the US Food and Drug Administration (FDA) Oncologic...
Robo Medical Secures Tens of Millions in Funding for EndoFaster and EndoDreams Development
China-based Robo Medical Technology Co. has closed a strategic funding round amounting to “tens of...
CanSino Bio Receives NMPA Approval for Phase I/II Trial of Recombinant Polio Vaccine
China-based CanSino Biologics Inc., (HKG: 6185) announced that it and its subsidiary CanSino (Shanghai) Biotechnology...
Yifan Pharma’s Generic Glycerol Phenylbutyrate Accepted for NMPA Review
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that the National Medical Products Administration (NMPA)...
Hengrui Pharmaceuticals’ SHR-8068 Gains NMPA Approval for NSCLC and Colorectal Cancer Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical...
Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao...